{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T10:28:13Z","timestamp":1776508093107,"version":"3.51.2"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004605","name":"Zhengzhou University","doi-asserted-by":"publisher","award":["212102310623"],"award-info":[{"award-number":["212102310623"]}],"id":[{"id":"10.13039\/501100004605","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.clcc.2022.11.005","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T07:53:46Z","timestamp":1669881226000},"page":"76-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["An Exploration of Trifluridine\/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study"],"prefix":"10.1016","volume":"22","author":[{"given":"Caiyun","family":"Nie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weifeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beibei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huifang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunduan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2022.11.005_bib0001","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clcc.2022.11.005_bib0002","doi-asserted-by":"crossref","first-page":"67","DOI":"10.21147\/j.issn.1000-9604.2022.02.01","article-title":"CSCO guidelines for colorectal cancer version 2022: updates and discussions","volume":"34","author":"Yuan","year":"2022","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.clcc.2022.11.005_bib0003","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2022.11.005_bib0004","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","article-title":"Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in asian patients with previously treated metastatic colorectal cancer: the TERRA study","volume":"36","author":"Xu","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2022.11.005_bib0005","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1586\/14737140.2015.1105746","article-title":"TAS-102 for the treatment of metastatic colorectal cancer","volume":"15","author":"Salvatore","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"10.1016\/j.clcc.2022.11.005_bib0006","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12307-015-0173-y","article-title":"Thymidine phosphorylase in cancer; enemy or friend?","volume":"9","author":"Elamin","year":"2016","journal-title":"Cancer Microenviron"},{"key":"10.1016\/j.clcc.2022.11.005_bib0007","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S1470-2045(17)30425-4","article-title":"TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1\/2 study","volume":"18","author":"Kuboki","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2022.11.005_bib0008","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","article-title":"TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial","volume":"21","author":"Pfeiffer","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2022.11.005_bib0009","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/oncolo\/oyab046","article-title":"A randomized phase II trial of mFOLFOX6\u00a0+\u00a0Bevacizumab Alone or with AdCEA Vaccine\u00a0+\u00a0Avelumab Immunotherapy for untreated metastatic colorectal cancer","volume":"27","author":"Redman","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2022.11.005_bib0010","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1186\/s12885-020-07169-6","article-title":"AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer","volume":"20","author":"Antoniotti","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clcc.2022.11.005_bib0011","doi-asserted-by":"crossref","first-page":"9243","DOI":"10.1200\/JCO.2005.07.740","article-title":"Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study","volume":"23","author":"Alberts","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2022.11.005_bib0012","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"Falcone","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2022.11.005_bib0013","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1200\/JCO.2007.15.4138","article-title":"Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study","volume":"26","author":"Hochster","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2022.11.005_bib0014","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","article-title":"Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials","volume":"3","author":"Tejpar","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clcc.2022.11.005_bib0015","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2022.11.005_bib0016","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial","volume":"319","author":"Li","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.clcc.2022.11.005_bib0017","first-page":"165","article-title":"current options for third-line and beyond treatment of metastatic colorectal cancer. Spanish TTD group expert opinion","volume":"19","author":"Fernandez-Montes","year":"2020","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2022.11.005_bib0018","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ctrv.2017.04.007","article-title":"Treatment decisions in metastatic colorectal cancer - beyond first and second line combination therapies","volume":"59","author":"Vogel","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clcc.2022.11.005_bib0019","article-title":"A comparison of bevacizumab plus TAS-102 and TAS-102 monotherapy for metastatic colorectal cancer: a systematic review and meta-analysis","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clcc.2022.11.005_bib0020","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S2468-1253(20)30396-4","article-title":"Safety and activity of trifluridine\/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial","volume":"6","author":"Kawazoe","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clcc.2022.11.005_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.764618","article-title":"Progress in the application of immune checkpoint inhibitor-based immunotherapy for targeting different types of colorectal cancer","volume":"11","author":"He","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clcc.2022.11.005_bib0022","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2022.11.005_bib0023","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jamaoncol.2020.0910","article-title":"Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian Cancer Trials Group CO.26 study","volume":"6","author":"Chen","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clcc.2022.11.005_bib0024","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.49040","article-title":"Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer: a randomized clinical trial","volume":"5","author":"Mettu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clcc.2022.11.005_bib0025","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2022.11.005_bib0026","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s10120-021-01271-9","article-title":"Efficacy and safety of trifluridine\/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)","volume":"25","author":"Shitara","year":"2022","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.clcc.2022.11.005_bib0027","first-page":"342","article-title":"Trifluridine\/Tipiracil in metastatic colorectal cancer: a UK multicenter real-world analysis on efficacy, safety, predictive and prognostic factors","volume":"20","author":"Stavraka","year":"2021","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2022.11.005_bib0028","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12885-017-3925-x","article-title":"Colorectal cancer liver metastases - a population-based study on incidence, management and survival","volume":"18","author":"Engstrand","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clcc.2022.11.005_bib0029","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jamcollsurg.2009.12.040","article-title":"Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution","volume":"210","author":"House","year":"2010","journal-title":"J Am Coll Surg"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002822001311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002822001311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:08:19Z","timestamp":1761520099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002822001311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1533002822001311"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2022.11.005","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Exploration of Trifluridine\/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2022.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}